Skip to main content
ARDELYX, INC. logo

ARDELYX, INC. — Investor Relations & Filings

Ticker · ARDX ISIN · US0396971071 LEI · 549300F542QR4SXHCY32 US Manufacturing
Open in API
Filings indexed 1,078 across all filing types
Latest filing 2019-06-14 Declaration of Voting R…
Country US United States of America
Listing US ARDX

About ARDELYX, INC.

https://www.ardelyx.com/

Ardelyx, Inc. is a biopharmaceutical company that discovers, develops, and commercializes first-in-class medicines to address unmet medical needs. The company's primary therapeutic areas of focus are cardiorenal and gastrointestinal diseases. Its key commercial product is XPHOZAH® (tenapanor), a novel mechanism therapy for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Ardelyx also develops treatments for Irritable Bowel Syndrome with Constipation (IBS-C), aiming to advance patient care through its portfolio of innovative therapies.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 14, 2019, reporting on the Annual Meeting of Stockholders held on June 13, 2019. It details the submission of matters to a vote, including election of directors and ratification of the independent registered accounting firm. The content focuses on the official results of shareholder votes at the Annual Meeting. The document length is 4396 characters, which is relatively short but contains detailed voting results. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), which covers official results from shareholder votes at any general meeting. It is not an Annual Report, Proxy Statement, or Management Information. Therefore, the correct classification is DVA with high confidence.
2019-06-14 English
FORM 4
Director's Dealing
2019-06-07 English
FORM 4
Director's Dealing
2019-06-07 English
FORM 4
Director's Dealing
2019-06-07 English
FORM 4
Director's Dealing
2019-06-07 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Ardelyx, Inc. It provides an update on the progress and projections of ongoing clinical trials, specifically mentioning expected data announcements in upcoming quarters. The document is relatively short (3393 characters) and focuses on a specific event update rather than comprehensive financial data or detailed reports. It does not contain full financial statements or detailed analysis typical of Annual Reports (10-K) or Interim Reports (IR). It is also not a certification, proxy, or voting result announcement. The content fits the category of a Regulatory Filing (RNS), which is a general category for miscellaneous filings that do not fit other specific categories, including event updates like this one.
2019-06-05 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.